Basic Information


GTO ID GTC2863
Trial ID NCT05144386
Disease HIV Infection
Altered gene HSV-1 genome
Therapeutic/Target gene Target gene
TherapyGene editing
Treatment EBT-101
PhasePhase1
Recruitment statusActive, Not Recruiting
TitleA Phase 1/2a, Sequential Cohort, Single Ascending Dose Study of the Safety, Tolerability, Biodistribution, and Pharmacodynamics of EBT 101 in Aviremic HIV-1 Infected Adults on Stable Antiretroviral Therapy
Year2021
CountryUnited States
Company sponsorExcision BioTherapeutics
Other ID(s)EBT-101-001
Vector information
Vectoradeno-associated virus
ConstructAAV9-CRISPR/Cas9
Vector typeadeno-associated virus serotype 9 (AAV9) vector
Transgene/Inserted geneHIV-1-specific clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing system

Clinical Result

Cohort 1
Administration route intravenous infusion
Pts 6
Age Adult, Older_Adult

Relationship Graph

Overview of Knowledge Graph